SeaStar Medical reports higher 90‑day survival for pediatric sepsis‑AKI patients using QUELIMMUNE
SeaStar Medical Holding Corp. presented late‑breaking data showing that pediatric patients with sepsis‑associated acute kidney injury treated with its QUELIMMUNE (SCD‑PED) device had a 65.1% 90‑day survival rate, compared with 47.4% in a historical cohort. The analysis included 43 treated patients versus 196 historical controls and found no device‑related adverse events. A landmark sensitivity analysis showed 63.8% versus 48.7% survival, though the difference was not statistically significant.
Why it matters
The survival benefit may improve investor sentiment toward SeaStar’s device portfolio, as reflected by a 3.51% after‑hours share price increase. The data could also influence reimbursement discussions and future market adoption.
Key facts
- 1Day‑90 survival was 65.1% for the QUELIMMUNE‑treated group versus 47.4% for the historical comparator. stocktitan.net
- 2No device‑related adverse events were reported among treated patients. stocktitan.net
- 3The primary analysis compared 43 QUELIMMUNE‑treated patients with 196 historical patients. rttnews.com
- 4Landmark sensitivity analysis showed 63.8% versus 48.7% day‑90 survival. rttnews.com
- 5ICU closed at $2.85, down 10.09%. rttnews.com
- 6After‑hours trading showed shares up 3.51% at $2.95. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.